Binding Energy calculation of GSK-3 protein of Human against some anti-diabetic compounds of Momordica charantia linn (Bitter melon)

• Published in: Bioinformation Vol. 8; no. 6; pp. 251 - 254
• Main Authors: Hazarika, Ridip, Parida, Pratap, Neog, Bijoy, Yadav, Raj Narain Singh
• Format: Journal Article
• Language: English
• Published: Singapore Biomedical Informatics 01.01.2012
• Subjects: Hypothesis; Momordica charantia; Momordica charantia; docking; Exome™ Horizon suite; GSK-3; anti-diabetic
• ISSN: 0973-8894; 0973-2063; 0973-2063
• DOI: 10.6026/97320630008251

Diabetes is one of the major life threatening diseases worldwide. It creates major health problems in urban India. Glycogen Synthase Kinase-3 (GSK-3) protein of human is known for phosphorylating and inactivating glycogen synthase which also acts as a negative regulator in the hormonal control of glucose homeostasis. In traditional medicine, Momordica charantia is used as antidiabetic plant because of its hypoglycemic effect. Hence to block the active site of the GSK-3 protein three anti-diabetic compounds namely, charantin, momordenol & momordicilin were taken from Momordica charantia for docking study and calculation of binding energy. The aim of present investigation is to find the binding energy of three major insulin-like active compounds against glycogen synthase kinase-3 (GSK-3), one of the key proteins involved in carbohydrate metabolism, with the help of molecular docking using ExomeTM Horizon suite. The study recorded minimum binding energy by momordicilin in comparison to the others.